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Objective: To explore doctors’ understanding of
individualisation of drug treatments, and identify the
methods used to achieve individualisation.
Design: In this exploratory study, we used in-depth
qualitative interviews with doctors to gain insight into
their understanding of the term ‘individualised
treatments’ and the methods that they use to achieve it.
Participants: 16 general practitioners in 6 rural and
10 urban practices, 2 geriatricians and 2 clinical
academics were recruited.
Setting: Primary and secondary care in South West of
England.
Results: Understanding of individualisation varied
between doctors, and their initial descriptions of
individualisation were not always consistent with
subsequent examples of the patients they had treated.
Understandings of, and methods used to achieve,
individualised treatment were frequently discussed in
relation to making drug treatment decisions. Few
doctors spoke of using strategies to support patients to
individualise their own treatments after the
consultation.
Conclusions: Despite its widespread use, variation in
doctors’ understanding of the term individualisation
highlights the need for it to be defined. Efforts are
needed to develop effective methods that would offer a
structured approach to support patients to manage
their treatments after consultations.
INTRODUCTION
Self-management is one of the foundations
of chronic disease management; however,
it is not straightforward. To facilitate self-
management, policymakers advocate that
treatments are tailored, personalised or indi-
vidualised to patients’ needs1 and that
patients are supported to self-manage their
conditions.2 Despite this, terms such as indi-
vidualisation and personalisation are regularly
used to refer to a number of different things.3
It is often unclear as to whether individualised
treatments are individualised to patients’
medical needs or their personal needs;3
which may or may not be complementary.
Successful pharmacological management
of chronic disease requires appropriate drug
prescription by doctors and appropriate drug
utilisation by patients. This involves (at least)
three processes. First, there is the interaction
between the doctor and the patient within
the medical consultation: the task here is to
make a correct diagnosis and select appropri-
ate treatments. Next is the doctor’s prescrip-
tion of appropriate drugs and dosage
schedules to treat the individual patient if
necessary. The third process is the patient’s
use of the drug in the context of their lives.
This process is not linear; interactions
between doctors and patients will occur both
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before and after the prescription has been written
and further interactions between patients and doctors
are likely to occur during follow-up consultations.
Treatments may be individualised at any stage.
Evidence-based guidelines are available to support
doctors to select appropriate drugs for individual
people.4 5 However, there remains a degree of uncer-
tainty regarding the effectiveness of certain pharmaco-
logical treatments for individual patients.6 Results of
randomised controlled trials cannot always be accurately
applied to different individuals in varying sociodemo-
graphic and medical contexts.7 8 Variation in the severity
of the condition, the presence of comorbidity, genetic
proﬁle, polypharmacy and psychosocial factors all inﬂu-
ence the effectiveness of the treatment and the potential
risk of adverse drug reactions.7 For individuals with mul-
tiple conditions, on multiple medications, or with a new
or rare condition, the guidelines are often unsuitable or
unavailable.9 A large body of research promotes models
of interaction or decision-making such as patient-
centered care10 and shared decision-making.11 These
are recommended by academics and policymakers as
potential solutions in which patients’ views and priorities
are explored and treatment decisions are negotiated.12
Despite the recommendations, these ‘solutions’ are not
routinely used in clinical practice,13 and there is very
little consensus about what these terms entail or how
they should be implemented.13–15
Previous qualitative research has explored how health-
care providers make individualised treatment decisions
in the face of competing priorities.16–18 That research
highlights the variation in the strategies doctors employ
to make treatment decisions in such situations.16–18
Doctors vary in their use of evidence and how they
resolve the tensions that are inherent in using evidence
alone (such as without consideration of patients’ prefer-
ences). When faced with complex patients, doctors
approach decisions with caution and uncertainty.16 19 20
Should a drug be prescribed, the third process is
the patients’ use of the drug after the consultation. In a
synthesis of qualitative studies of medication taking,
Pound et al21 found that patients’ use of medication is
inﬂuenced by their judgements about the relative risks
and beneﬁts of using medications, the likelihood and
impact of adverse effects and the acceptability of the
treatment regime in their lives. Pound et al21 also found
evidence to suggest that patients are often motivated to
minimise their use of medication—to reduce the dose
of medication while still achieving some gain or to make
the regime more acceptable or cost-effective. Patients
actively sought answers to questions they had about their
medication, for example, by stopping or lowering the
dose of medication to test its effectiveness (lay testing);
only taking medication when symptomatic (symptomatic
use of medication); only taking medication or taking
more medication to offset lifestyle factors such as
drinking alcohol (strategic use of medication) and
replacement of medication with non-pharmacological
treatments. Thus, many patients carry out their own indi-
vidualisation according to their own criteria.
This project aims to explore doctors’ understanding of
the term ‘individualised treatments’ and the methods
that they employ to achieve individualised treatments.
METHODS
Design
In this exploratory study, we used in-depth qualitative
interviews22 with doctors to explore their understanding
and clinical practice.
Sampling and data collection
We used opportunity sampling to recruit doctors to the
study. We anticipated that individualisation would be par-
ticularly relevant to doctors who deal with patients who
have a range of problems; therefore, we decided to
sample doctors who are generalists (such as general
practitioners (GP) and geriatricians). Two clinical aca-
demics (who were also hospital consultants) from within
the medical school took part in pilot interviews to help
test the procedure and topic guide.
We then emailed information about the study to 55 prac-
tice managers from practices on the Devon Primary Care
Incentive Scheme register (a register of primary care prac-
tices who have applied for support from the Primary Care
Research Network for participation in research), and asked
interested doctors to make contact and arrange a time and
place for the interview to take place. Sixteen doctors from
12 primary care practices responded to the email and took
part in the interview. Two geriatricians were also recruited
using snowball sampling. Our initial topic guide was based
on a review of the literature and our own clinical experi-
ence (an experienced nurse and a rheumatologist are
members of the team). Open-ended questions were used
to explore the following topics (1) understanding of indi-
vidualisation, (2) examples of individualising treatments,
(3) methods used when patients’ preferences are incom-
patible with guideline recommendations, (4) methods
used to support patients to use their medication outside
consultations, (5) methods used to individualise treatments
for patients with multiple chronic conditions and (6) when
individualisation is and is not appropriate. Participants
were also asked if there was anything else they thought was
relevant to individualisation. On the basis of the two pilot
interviews with local clinical academics, the topic guide was
modiﬁed to make it clear that we were interested in indivi-
dualised drug (as opposed to talking or physical) treat-
ments in patients with chronic (as opposed to acute)
conditions. In order to obtain detailed accounts, doctors
were encouraged to provide examples of patients they had
seen whenever possible.
To contextualise our study, the interviewer gave the
following explanation at the beginning of the interview:
“Patients will vary in terms of the number of conditions
they have, the amount of medications they take, and the
severity of their condition(s). Patients will also have very
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different lifestyles, priorities and beliefs about their con-
dition(s) and treatments. We aim to explore the
methods used by Healthcare providers to individualise
treatments. We are aware that there is little consensus
about what individualisation is, little guidance in the lit-
erature about how to do it, and that some doctors have
developed their own approaches. We are interested in
exploring the methods or strategies that are used by
healthcare providers to tailor treatments to each individ-
ual patient.” The interviewer started interviews by asking
participants what they understood individualisation
to be, and to provide an example of a time during
which they had individualised treatment with a patient.
To avoid inﬂuencing participants’ answers, we did not
explicitly deﬁne individualisation. However, the inter-
viewer later used prompts to encourage participants to
discuss additional situations that could be considered
to be amenable to individualisation (as per the topic
guide). We anticipated that this would provide a detailed
account of doctors’ understanding of individualisation
and the methods that they would use to achieve it within
their understanding, as well as the methods that they
used to individualise treatments as others may see it.
All participants provided written consent prior to taking
part. Ethical approval was obtained from the Peninsula
College of Medicine and Dentistry ethics committee.
Data analysis
Interviews were audio recorded, anonymised and tran-
scribed verbatim. We analysed the data using a thematic
approach.23 Two researchers independently read tran-
scripts and noted down core codes that were identiﬁed.
We met regularly to discuss codes and to develop a pre-
liminary list of themes. As analysis progressed, we drew
on the existing literature to reﬁne this list and to group
related themes together.24
We then developed a chart for each theme,24 and
copied any interview data that were related to each
theme into the relevant chart. To enhance rigour,25 two
authors carried out this process independently. We
resolved discrepancies via discussion.26 We then used the
charts to identify narratives within cases and diversity
between cases.27 Divergent cases were discussed and
included in the thematic analysis.27
A summary of the ﬁndings was sent to all doctors
along with an invitation to offer any comments.
RESULTS
One author (SD) collected data between February and July
2012 from 16 GPs (6 rural and 10 urban practices) and 2
geriatricians from clinical practices in Devon. Data from
the two clinical academics who took part in the pilot inter-
views were also included in the analysis. Seven doctors were
women. Interviews were held at a location to suit the
doctors (mainly at their place of work). The mean length
of the interviews was 48 min (range 20–60 min). The data
are presented under three main headings. First, we
identiﬁed two subthemes relating to doctors’ understand-
ing: evidence-based medicine and doctor-led prescribing,
and individualising treatments around patient factors.
Second, we identiﬁed two subthemes under the heading
methods used to individualise treatments: methods used to
make treatment decisions during the consultation, and
methods to support patients after the consultation. Third,
we identiﬁed dissonance between the rhetoric of individu-
alisation and doctors’ clinical reports of how they had dealt
with some of their patients. In the following quotations, all
names are pseudonyms.
Understanding of individualised treatment
Doctors’ understanding of individualisation ranged from
evidence–based, medically focused doctor-led care,
through to prescribing drug treatments tailored to the
patients’ wishes and beliefs. There was variation in the
ease with which doctors spoke about individualisation.
There were two doctors who could not articulate their
understanding of individualisation, but who were still
able to respond to prompts about how they would deal
with situations that could be considered to be amenable
to individualisation. Doctors frequently discussed indi-
vidualisation in relation to two of the processes involved
in the prescription and use of pharmacological
treatment—selecting appropriate drugs to treat the indi-
vidual patient, and the interaction with the patient in
the medical consultation. Doctors paid less attention to
patients’ use of treatments postconsultation.
Evidence-based medicine and doctor-led prescribing
At one end of the spectrum, individualisation was consid-
ered to be synonymous with evidence-based practice.
Focusing on the doctor’s task of selecting appropriate
drugs to treat the individual patient, one doctor
described how the process of matching patients with
guidelines resulted in all treatments being individualised:
I suppose when I did discuss it recently with my colleague
the point he made was all treatments are individualised
and it’s, perhaps you’re looking at it from a different per-
spective, because we look at it from the individual that
comes in and then try and match a guideline to them or
guidance, so everything you do is individualised anyway.
(Sophie, urban GP)
Importantly, when asked about their understanding
of individualised treatment, no doctor referred to
doctor-led prescribing speciﬁcally. However, it was impli-
cit in their examples that in certain situations (such as if
the doctor thought that the patient really could beneﬁt
from treatment), they considered a doctor-led style of
prescribing to be individualised.
Well again, it’s a case of looking at what is right for that
particular patient at that particular time, and, I, I,
because the patient was at high risk of stroke, then I did
really try to push the treatment. ( Jim, urban GP)
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You know, because I think if, somebody might be very
against a drug, but if I’ve seen it work really effectively in
the past, I suppose I feel, I wouldn’t force them to take
it, if I force them to take it they won’t take it anyway, but
I suppose I feel if I can ﬁnd a way round it that would
encourage them just to give it a go, sometimes it’s worth
it. (Catherine, urban GP)
Individualising treatments around patient factors
Doctors described individualised treatments as drug
treatments that had been selected after consideration
of patient factors (such as patient circumstances).
Frequently, this meant adapting or going against guide-
line recommendations. Some doctors described indivi-
dualised treatments as treatments that had been tailored
to suit the patients’ medical needs (eg, when treating
patients with comorbidities):
Well it’s always checking on individual preferences, but
the biggest factor is co-morbidity, that’s what makes me
step outside the box as it were. (Tom, urban GP)
For other doctors, individualised treatments were treat-
ments that had been adapted to suit patients’ social
circumstances
So, I’ve got someone who lives out the back of beyond, no
transport, they might be less keen to have something that
requires frequent monitoring … We have a lot of shift
workers round here so that can be quite an issue, um,
shifts will often change from week to week … complete
nightmare controlling anything like that because they’re
sometimes asleep when they’re supposed to be taking
their pills. So they can be tricky. (Rachel, rural GP)
For some, individualised treatment required the
patient to be involved in treatment decisions; with treat-
ments being individualised around the patient’s willing-
ness to take a drug. These doctors considered patients’
preferences to be more important than their own views
and preferences. In particular, the two geriatricians in
our sample were conscious that the patients’ preferences
are perhaps more important than achieving optimal
control of their conditions:
Because most of the patients that we see have reached
what statistically would be regarded as their life expect-
ancy. So there is, we can’t in anyway force our opinions
on them. We have to go with the fact that they have
made this value judgement as to what is the right thing
for them … And we just have to accept that they’ve made
the right judgement for them. Which is not necessarily
the right judgement for us. But as long as we feel that
they are fully informed, or as informed as they can be,
then we just accept what decisions they make on their
behalf. (Mark, geriatrician)
Maybe that’s easier in geriatrics where we know lots of what
we do comes at a price, we know 10% of hospital admissions
that we do are from drug side effects. So maybe we feel a bit
more relaxed about it. (William, geriatrician)
For others, individualising treatment in accordance
with the patients’ willingness to take a drug simply meant
accepting that the patient had declined treatment
And I’m quite happy to agree to differ, if they want to
decline treatment, I’d write down declined treatment.
I think it’s important to come back to, not just see it as
something that they’ve done wrong, but it’s ﬁne for them
to do that, and I don’t have a problem with them not
taking that treatment. (Marcus, urban GP)
Methods used to individualise treatments
Doctors described the methods they used to achieve
individualisation. Again, doctors focused on the
methods used to select appropriate drugs to treat indivi-
duals and interactions with the patients during the con-
sultation. Few doctors spoke of methods to support the
patient in using treatments after the consultation when
drug taking actually occurs.
Methods used to make treatment decisions during
the consultation
Doctors described using a range of resources to select
appropriate drugs to treat individual patients. These
included evidence, clinical experience, colleague
support and the patients’ views or circumstances. Use of
resources was dependent on the doctors’ understanding
of individualisation, but inﬂuenced by the patient and
the situation. All doctors described using evidence to
make treatment decisions. However, views about the role
of the evidence varied between doctors
EBM is only one of many strategies, and, it’s like you’ve
got a tool box you know? And the tool that you use every
time is you yourself. And you need, and you can learn to
do that better. I’m very interested in that. And then occa-
sionally you’ll pull EBM out as well. But not, you know,
not very often. Honestly, I would think I probably, as a
ﬁrst tool that you pull out, it would probably be once or
twice a day. (Andrew, urban GP)
It was widely acknowledged that ‘text book’ scenarios
were rare. One GP reported that most of his patients
had complex social needs, and both the geriatricians in
our sample reported that nearly all their patients had
multiple conditions. These complex patients could not
be treated using only evidence-based guidelines.9
Treatment decisions for patients with complex needs
were made based on their own or their colleagues’ clin-
ical experience
Often we send messages to each other. I share a list with
another GP colleague, and we share difﬁcult patients,
and discuss how are we going to get Mr so and so to do
X, Y and Z? (Sophie, urban GP)
To treat patients with complex needs, doctors often
made treatment decisions for the patient, using strat-
egies like polypharmacy to deal with side effects of
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treatments, and accepting that not all conditions can be
optimally managed
Interviewer (I): Ok, so when you’ve got a patient who
comes in and has a range of medical conditions, and you
know if you treat all of them it’s going to lead to interac-
tions? Respondent (R): The regimens for each of these
conditions, A, B and C are reasonably well sorted because
they’re common conditions, common drugs, usually
sorted. So he has arthritis, diabetes and epilepsy. That’s a
nice juicy mix, and fairly common. By and large you will
get away with this polypharmacy. (Mathew, urban GP)
To involve the patient in the treatment decisions,
doctors reported using techniques such as providing the
patient with the information needed to make an
informed choice, suggesting treatment and outcome
options, and giving the patient time to think about
their priorities
And then we can provide them with alternatives like ‘well
this will cure that but this could affect your kidneys. This
might not have as big an effect on that but it would pre-
serve the kidneys and could leave you a little bit short of
breath. Of those two which would you rather have? The
risk of feeling completely healthy, but potentially shorter
life, or having some symptoms but a longer life?’ And
working with those decisions. (Mark, geriatrician)
While one doctor aimed to prescribe treatments in
accordance with the patient’s interests, he accepted that
this could not be an everyday occurrence
I’ll be honest; I don’t do it all the time, so I don’t want to
pretend I’m perfect at this. I think the clearest one that
I’ve got is a bloke in his late 50s with Parkinson’s who’d
retired, but the thing that kept him going was that he
could go to the swimming pool every morning … So we
opted for a patch for him … You slap it on once a day
and it gives you 24 hour coverage so he could put it on
the night before and he’d be switched on in the
morning, he wasn’t waiting for a tablet to kick in and
make him work. And it worked beautifully for him … but
after a few months he got skin reactions and we had to
stop it and ﬁnd something else, but that really felt like we
had really picked a drug around him and his interests
and what was keeping him going. (William, geriatrician)
Interviewees also reported situations in which a more
direct approach was considered to be necessary. This
included situations in which the patient’s goals were
deemed unrealistic, or when the doctor thought that
the patient really should be using some form of treat-
ment. Doctors then reported using techniques in order
to convince or persuade the patient to follow recom-
mendations. In some cases, attempts were made to
encourage the patient to see the medical imperative for
treatment
They don’t want to take any tablets; you say ‘well you
probably will die in 5 years time at the most without these
things. If you take these things it might prolong your life,
by this that or the other.’ ( Joe, urban GP)
For some doctors, the assumption appeared to be that
the patient was in some way misinformed. Therefore,
attempts were made to educate the patient
Most of the time you can explain to people why they
ought to be taking something and hopefully they might
come round to thinking that that’s the best thing to do.
Sometimes people might have different ideas and won’t
take anything or certainly won’t take what you suggest
but I think most of the time you can explain to people
why or what the evidence is or what the consensus is.
And most of the time if people understand it they’ll take
it. (Lynn, rural GP)
If initial treatment decisions were not acceptable to
the patient, attempts were made to change or simplify
the regime or to prescribe alternative treatments
You just say ‘well let’s try something else.’ The nice thing
is, there’s always, or very often there’s always alternatives
that are either as good or, uh, you know, in the same
league. (Sophie, urban GP)
Methods used to support patients after the consultation
In most interviews, individualisation was described in the
context of making treatment decisions during the con-
sultation. Few doctors spoke of methods to support
patients to test and reﬁne their treatment in the context
of their own life. To support patients after the consult-
ation, doctors reported using techniques such as remin-
ders and instructions. This ranged from standardised
monitored dosage systems or text messaging services, to
writings and drawings on prescription labels. Crucially,
the aim of such strategies was to help the patient use
their medications as prescribed
I: Do you use any strategies to support the patients
outside the consultation? R: Um, not enough. It’s some-
thing I often think about that I should be doing more.
So I do drawings and write things on bits of scrap paper,
about if there is a complicated medication, or a list of
things to do, or if people are older, forgetful (Marcus,
urban GP)
A minority of doctors described using strategies to
help patients modify treatment regimes to suit their
lives. One geriatrician described how he used techniques
such as separating drugs into those that have to be taken
(to treat the condition) and those that do not have to
be taken (to treat the symptoms)
I tend to rearrange them so into treatments and symp-
toms … And if you group them like that, then if they get
half way through the tablets, providing they’ve taken
their treatment tablets, the symptom control, if they
don’t take it they’re going to feel lousy, but the balance
between taking a tablet or not taking a tablet, it’s not
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going to make any difference to their longer term
health. (Mark, geriatrician)
Another geriatrician described a process of trial and
error, in which drugs were used for a period of time and
then modiﬁed by the doctor if necessary
I think as well, because we tell patients for a lot of these
drugs let’s try this and see if it works, if it’s not working
we’ll stop it. It allows patients to come back and say it’s
not working rather than come back and feel that they’re
on it. (William, geriatrician)
Only one GP actively encouraged patients to modify
their treatments to achieve individualised doses. This
doctor described a reluctance on the part of some
patients to do so
So actually, for an awful lot of drugs, I do this all the
time. I say balance up your, you know yourself when
you’re getting the side effects. Titrate the medication
until you’re just below the level at which you get the side
effects and ﬁddle around with it … And then sometimes
the patients say, ‘ohh, but it says once a day and bla bla
bla. ( Joe, urban GP)
The hospital consultants in our sample reported using
diaries and graph paper to either assess the effectiveness
of treatments and treatment doses, or to encourage
patients to respond to worsening symptoms
So, it’s just a piece of paper really with days of the week
and what their Parkinson’s is like. But Parkinson’s you
swing from being on, when you can move around, to
being off, when you’re frozen and stuck. So if we’re
trying to give a drug to reduce the amount of time
people are off, we’ll often give them a diary so you can
graphically see whether it’s worked or not. (William,
geriatrician)
Well they all get the graph paper. And it’s “If it goes
above this line, phone us and we’ll see you in clinic
straight away. Or, if it goes above this line increase your
tablets. Or do this that or the other.” And it’s what we tell
them to do when it reaches that point that varies by
patients. (Mark, geriatrician)
The question of whether or not patients needed to be
encouraged to monitor symptoms was contested. Some
doctors were of the opinion that patients should not be
encouraged to monitor their symptoms or side effects of
their treatments
I quite often don’t tell people about the side effects of
tablets, which is against our, against all the modern day
teachings that you must tell people of the risks. Well
I often don’t. Because there’s a lot of evidence for this,
there’s a type of patient that if you tell them there is a
possibility that they’ll get headaches, they’ll get head-
aches. ( John, clinical academic)
Others felt that patients should be told what potential
side effects they should look out for
Explain to them the possibility that one thing might
affect another and what to look out for. So if there are
going to be interactions, what they, what they need to be
um, coming back with um, if certain symptoms present.
You know if you get this, come back, because that’s a side
effect we need to know about. (Becky, urban GP)
However, even with clear instructions, mistakes could
happen
We’ve had that with a patient who used, you know, he
had the line [indicating safe blood pressure readings],
he went way below the line, kept on going without both-
ering to phone anyone, and six weeks later he was in hos-
pital with renal failure. And we gave him pretty clear
instructions. He decided to ignore them … It worked; he
just didn’t follow the instructions. But you can’t do any-
thing about that. Patients are entitled to do what they
want. (Mark, geriatrician)
There was wide acceptance that, in the end, the ﬁnal
treatment decision was down to the patient. In certain
situations, no treatment could be the best option
You know, you say, ‘this is what’s going on, you tried them
we’ve looked at physiotherapy, we’ve looked at other
alternatives, are your symptoms manageable? Are the
treatments worse than the condition, and if they are,
then maybe you need to learn to live with the condition.
(Rachel, rural GP)
Dissonance between rhetoric and experience
While all but two doctors were able to describe their
understanding of individualisation when asked, these
answers did not always match the examples they provided
when talking about patients they had treated. For
example, one doctor described individualisation as being
All sorts of things. Everything from the persons’ views or
thoughts about—if you’re talking about medicines—
about drugs and what they want. But similarly that ﬁts
with their views of whether they like medicine, don’t like
medicine, what they want in terms of getting better.
(Catherine, urban GP).
However, when this participant was asked how she
would respond to a patient who did not want to use the
treatment that she had prescribed, she responded
There are even times when I’ll say ‘well actually I think this
would be worth trying’ even if they’re not very keen. And
I’ll say to them ‘how about you give it a go for two weeks
and see how you feel.’ You know, because I think somebody
might be very against a drug, but if I’ve seen it work really
effectively in the past, I suppose I feel, I wouldn’t force
them to take it, if I force them to take it they won’t take it
anyway, but I suppose I feel if I can ﬁnd a way round it that
would encourage them just to give it a go, sometimes it’s
worth it. (Catherine, urban GP)
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This dissonance between rhetoric and experience was
evident throughout the interviews. While doctors
appeared to think that individualising treatments
around patients’ preferences and world views into treat-
ment decisions was of value, in practice this was not
always considered to be the best strategy.
DISCUSSION
Main findings and comparisons with other studies
This paper presents a range of doctors’ understandings
of the meaning of individualised drug treatment.
Individualised treatment was discussed in relation to
both treatment that was tailored to patients’ priorities,
and treatment that was doctor-led and followed
evidence-based guidelines. Furthermore, there was a
lack of congruence between doctors’ stated deﬁnition of
individualisation and the examples they provided from
their practice. Doctors frequently spoke of methods to
support interactions during consultations, the ﬁrst of the
processes referred to in the introduction of this paper.
However, despite the ﬁndings of Pound et al,21 doctors
in our study infrequently mentioned patients’ use of
their medications outside the consultations.
The main strength of this study is the use of qualitative
methods to generate a rich insight into doctors’ under-
standing of individualisation, methods used to achieve
individualisation and the relationships between the two.
We used strategies to enhance the trustworthiness of our
study, including multiple coders and respondent valid-
ation. We triangulated our ﬁndings with the existing lit-
erature, and asked participants to comment on our
ﬁndings.28 Participants who took part in pilot interviews
stated that they could recognise our ﬁndings, and
agreed that they were plausible.
Our study was based on a sample of hospital consul-
tants and GPs from the South West of England. That
doctors were recruited only from this area could limit
the transferability of the results, although participants
had both trained and practised beyond this region. We
acknowledge that our use of opportunity sampling may
have resulted in a self-selected sample. However, as
we are interested in best practice, we were not overly
concerned with recruiting only those with an interest in
the study.
Previous qualitative research has explored methods to
support doctors during consultations.16–18 In those
studies, the focus was on strategies used by doctors to
make individualised prescribing decisions within the
medical consultation—where guidelines may not be
appropriate. Similar to the doctors in our study, those
studied by Fried et al had varied views about how treat-
ment decisions for patients with complex conditions
should be made. Use of evidence and strategies to
balance the harms versus the beneﬁts of guideline-
directed care varied between physicians.
Doctors in both these studies had differences of
opinion regarding the role of the patient in treatment
decisions. For some, treatment decisions should be
doctor-led, with the doctor persuading the patient to
use the treatment that they thought would be most
appropriate. For others, patient involvement was an
essential component of treatment decisions. A number
of doctors reported that integrating patients’ prefer-
ences into medical decisions was problematic if the treat-
ment was essential. This was still a major concern for
many doctors, despite research suggesting that patients’
and doctors’ priorities may be very different.29 This
paternalism versus patient choice is an ongoing debate,
and one that is widely discussed in the literature.15 30 31
In the current paper, the dissonance between the rhet-
oric of individualisation and doctors’ clinical behaviour
appeared to stem from this issue, with the data revealing
tensions between the doctors’ desire to treat the
patients’ social needs, while simultaneously treating
their medical needs.
Pound et al21 found evidence to suggest that patients
actively modify their medications in order to suit their
lives. However, there is a paucity of literature surround-
ing the methods used to support patients during this
third process. The few doctors in our study who spoke
of methods to support patients outside the consultation
described methods such as sorting drugs by their role
(to treat or to cure), trial and error, and monitoring.
These strategies are largely informal: for example, draw-
ings, or writing about the use of the medication on bits
of paper. The limitations of such informal methods were
acknowledged.
The lack of consideration of what goes on outside the
consultation is particularly interesting and worrying.
Pound et al have shown that many patients will monitor
their symptoms and side-effects and make treatment
adaptations as necessary—with or without the support of
the doctor. Self-management of chronic disease requires
patients to take multiple treatments and monitor their
health over many years. Therefore, strategies to support
patients to modify treatments, and providing safe para-
meters for them to do so, may actually limit patient
driven amendments to treatments without professional
support. However, our study highlights the variation in
opinions about whether or not patients should be
encouraged to adapt treatments after consultations. One
doctor felt that patients did not want to adapt their
treatments. Another doctor thought that encouraging
patients to be aware of the side effects could actually
contribute to side-effects. Others were concerned that
encouraging patients to monitor symptoms could lead to
unnecessary stress. Only a small number of doctors
thought that patients should be encouraged to individu-
alise treatments after the consultation. In particular, the
two geriatricians seemed to have a better understanding
of and a larger set of methods to support patients to
individualise treatments after consultations than the
GPs, thus suggesting that the ﬁndings might be related
to medical subspecialty. Further research is needed to
explore differences in individualisation between
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different clinical specialities, as this may highlight
situations in clinical areas in which individualisation is
commonly achieved, and situations in which individual-
isation is not so appropriate.
The ﬁndings reported here have important implica-
tions for research and practice. The focus of this study
was on the strategies and methods that doctors used to
reach decisions within the consultation. Few doctors dis-
cussed methods to support patients to use drug treat-
ments outside the consultation. Methods that were
suggested were informal and unstructured, and doctors
acknowledged that such methods may neither be sup-
portive enough or measurable. Furthermore, doctors
perceived a number of barriers to individualising treat-
ments after the consultation, such as whether or not
strategies could contribute to side effects and cause
unnecessary stress. Before policy recommendations con-
cerning both individualisation and self-management can
be achieved, policymakers need to be clear about what
they are advocating, and thus the concept of individual-
isation needs to be reﬁned. Methods used to achieve
individualisation may then be developed and piloted in
different situations. Such methods should be appropri-
ately structured to be supportive and their effects
measurable. Given that some patients are already indivi-
dualising treatments on their own, supporting patients
to do so safely could improve patients’ self-management
practices.
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